<DOC>
	<DOC>NCT01525199</DOC>
	<brief_summary>The purpose of this trial is to compare the evolution of patients receiving first line treatment for locally advanced or metastatic lung cancer, taking into account if they were requested or not the EGFR mutation test as part of the diagnosis and treatment strategy. There is no assignment to any particular therapeutic strategy.</brief_summary>
	<brief_title>Diagnosis and Treatment Strategies in Patients With NSCLC With or Without EGFR Mutations.</brief_title>
	<detailed_description>Study of cases and controls on diagnosis and treatment strategies in patients with NSCLC with or without EGFR mutations.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<criteria>Patients with confirmed diagnosis of lung adenocarcinoma, stage IIIb/IV. Patients under 1st line treatment against lung adenocarcinoma. Patients not having the information required by the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Non-Small Cell Lung Cancer,</keyword>
	<keyword>Epidermal Growth Factor Receptor mutation,</keyword>
	<keyword>Lung cancer,</keyword>
	<keyword>Lung adenocarcinoma</keyword>
</DOC>